Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Treprostinil 0.6 MG/ML Inhalant Solution [Tyvaso]

Known as: Tyvaso (treprostinil 1.74 MG) per 2.9 ML Inhalant Solution, TYVASO 1.74 MG/2.9 mL (0.6 MG/mL) Inhalant Solution, treprostinil 1.74 mg in 2.9 mL ORAL INHALANT [TYVASO] 
 
National Institutes of Health

Related topics

Related topics

10 relations
Hydrochloric AcidInhalant SolutionSodium ChlorideSodium Hydroxide
Expand

Broader (2)

Treprostinil 0.6 MG/ML Inhalant SolutionTreprostinil Inhalant Solution [Tyvaso]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
INSPIRE: Final Results from a Phase 3, Open-Label, Pivotal Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension.
OF OBJECTIVES Significant advantages are associated with inhaled therapies for pulmonary arterial hypertension (PAH), including… Expand
2019
2019
INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) (Investigation of the Safety and Pharmacology of Dry Powder…
Summary of Objectives Inhalational drug delivery to treat PAH is attractive due to enhanced pulmonary specificity and reduced… Expand
2014
2014
Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension
Introduction : Inhaled treprostinil (Tyvaso™) for pulmonary arterial hypertension (PAH) is dosed 4 times daily. In an effort to… Expand
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE